Journal Article The Efficacy of Rituximab in High-risk Renal Transplant Recipients

Araki, Motoo  ,  Wada, Koichiro  ,  Mitsui, Yosuke  ,  Kubota, Risa  ,  Yoshioka, Takashi  ,  Ariyoshi, Yuichi  ,  Kobayashi, Yasuyuki  ,  Kitagawa, Masashi  ,  Tanabe, Katsuyuki  ,  Sugiyama, Hiroshi  ,  Wada, Jun  ,  Watanabe, Masami  ,  Watanabe, Toyohiko  ,  Hotta, Katsuyuki  ,  Nasu, Yasutomo

70 ( 4 )  , pp.295 - 297 , 2016-08 , Okayama University Medical School
Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.

Number of accesses :  

Other information